Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 6/2011

01-12-2011

Up-Regulation of the Inflammatory Response by Ovariectomy in Collagen-Induced Arthritis. Effects of Tin Protoporphyrin IX

Authors: Lidia Ibáñez, Maria José Alcaraz, Nuria Maicas, David Guede, José Ramón Caeiro, Marije I. Koenders, Wim B. van den Berg, Maria Luisa Ferrándiz

Published in: Inflammation | Issue 6/2011

Login to get access

Abstract

We have studied the influence of ovariectomy on the inflammatory response and bone metabolism on CIA as a model of postmenopausal arthritis as well as the effects of tin protoporphyrin IX (SnPP), a heme oxygenase inhibitor. Ovariectomy in non-arthritic mice produced increased serum PGD2 levels and up-regulated the expression of COX-2, h-PGDS, l-PGDS, and HO-1 in the joints. In CIA, ovariectomy potentiated the inflammatory response with higher levels of serum IL-6 and MMP-3, local PGD2 and MMP-3 as well as trabecular bone erosion. In OVX-CIA, SnPP decreased the serum levels of IL-6, MMP-3, and PGD2; down-regulated TNFα, COX-2, hPGDS, PGD2, PGE2, and MMP-3 in joint tissues; and also decreased focal bone loss in the inflamed joint. Ovariectomy up-regulates inflammatory mediators in non-arthritic and in arthritic animals. In the OVX-CIA model, SnPP exerts anti-inflammatory effects which are not associated with the prevention of systemic bone loss.
Literature
1.
Goldring, S.R., and E.M. Gravallese. 2000. Mechanisms of bone loss in inflammatory arthritis: Diagnosis and therapeutic implications. Arthritis Research 2(1): 33–37.PubMedCrossRef
2.
Forsblad, D.H., A. Larsen, E. Waltbrand, G. Kvist, D. Mellstrom, T. Saxne, C. Ohlsson, E. Nordborg, and H. Carlsten. 2003. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Annals of the Rheumatic Diseases 62(7): 617–623.CrossRef
3.
Goemaere, S., C. Ackerman, K. Goethals, F. De Keyser, C. Van der Straeten, G. Verbruggen, H. Mielants, and E.M. Veys. 1990. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. The Journal of Rheumatology 17(12): 1620–1622.PubMed
4.
D’Elia, H.F., A. Larsen, L.A. Mattsson, E. Waltbrand, G. Kvist, D. Mellstrom, T. Saxne, C. Ohlsson, E. Nordborg, and H. Carlsten. 2003. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. The Journal of Rheumatology 30(7): 1456–1463.PubMed
5.
Engdahl, C., C. Jochems, S.H. Windahl, A.E. Borjesson, C. Ohlsson, H. Carlsten, and M.K. Lagerquist. 2010. Amelioration of collagen-induced arthritis and immune-associated bone loss through signaling via estrogen receptor alpha, and not estrogen receptor beta or G protein-coupled receptor 30. Arthritis and Rheumatism 62(2): 524–533.PubMed
6.
Jochems, C., U. Islander, M. Erlandsson, M. Verdrengh, C. Ohlsson, and H. Carlsten. 2005. Osteoporosis in experimental postmenopausal polyarthritis: The relative contributions of estrogen deficiency and inflammation. Arthritis Research & Therapy 7(4): R837–R843.CrossRef
7.
Alcaraz, M.J., P. Fernandez, and M.I. Guillen. 2003. Anti-inflammatory actions of the heme oxygenase-1 pathway. Current Pharmaceutical Design 9(30): 2541–2551.PubMedCrossRef
8.
Zwerina, J., S. Tzima, S. Hayer, K. Redlich, O. Hoffmann, B. Hanslik-Schnabel, J.S. Smolen, G. Kollias, and G. Schett. 2005. Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. The FASEB Journal 19(14): 2011–2013.PubMed
9.
Chae, H.J., H.Y. Chin, G.Y. Lee, H.R. Park, S.K. Yang, H.T. Chung, H.O. Pae, H.M. Kim, S.W. Chae, and H.R. Kim. 2006. Carbon monoxide and nitric oxide protect against tumor necrosis factor-alpha-induced apoptosis in osteoblasts: HO-1 is necessary to mediate the protection. Clinica Chimica Acta 65(1–2): 270–278.CrossRef
10.
Lin, T.H., C.H. Tang, S.Y. Hung, S.H. Liu, Y.M. Lin, W.M. Fu, and R.S. Yang. 2010. Upregulation of heme oxygenase-1 inhibits the maturation and mineralization of osteoblasts. Journal of Cell Physiology 222(3): 757–768.
11.
Devesa, I., M.L. Ferrandiz, M.C. Terencio, L.A. Joosten, W.B. van den Berg, and M.J. Alcaraz. 2005. Influence of heme oxygenase 1 modulation on the progression of murine collagen-induced arthritis. Arthritis and Rheumatism 52(10): 3230–3238.PubMedCrossRef
12.
Joosten, L.A., E. Lubberts, P. Durez, M.M. Helsen, M.J. Jacobs, M. Goldman, and W.B. van den Berg. 1997. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis & Rheumatism 40(2): 249–260.CrossRef
13.
Kind, P.R., and E.J. King. 1954. Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine. Journal of Clinical Pathology 7(4): 322–326.PubMedCrossRef
14.
Moroney, M.A., M.J. Alcaraz, R.A. Forder, F. Carey, and J.R.S. Hoult. 1988. Selectivity of neutrophil 5-lipoxygenase and cyclo-oxygenase inhibition by an anti-inflammatory flavonoid glycoside and related aglycone flavonoids. The Journal of Pharmacy and Pharmacology 40(11): 787–792.PubMedCrossRef
15.
Feldkamp, L.A., L.C. Davis, and C. Krettek. 1984. Practical cone-beam algorithm. Journal of the Optical Society of America A 1(1): 612–619.CrossRef
16.
Hildebrand, T., and P. Rüegsegger. 1997. A new method for the model-independent assessment of thickness in three-dimensional images. Journal of Microscopy 185(1): 67–75.CrossRef
17.
Ulrich, D., B. van Rietbergen, A. Laib, and P. Ruegsegger. 1999. The ability of three-dimensional structural indices to reflect mechanical aspects of trabecular bone. Bone 25(1): 55–60.PubMedCrossRef
18.
Kong, Y.Y., U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, C. Capparelli, J. Li, R. Elliott, S. McCabe, T. Wong, G. Campagnuolo, E. Moran, E.R. Bogoch, G. Van, L.T. Nguyen, P.S. Ohashi, D.L. Lacey, E. Fish, W.J. Boyle, and J.M. Penninger. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402(6759): 304–309.PubMedCrossRef
19.
Stolina, M., B. Bolon, D. Dwyer, S. Middleton, D. Duryea, P.J. Kostenuik, U. Feige, and D.J. Zack. 2008. The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis. Biomarkers 13(7): 692–712.PubMedCrossRef
20.
Geusens, P.P., R.B. Landewe, P. Garnero, D. Chen, C.R. Dunstan, W.F. Lems, P. Stinissen, D.M. van der Heijde, L.S. Van Der, and M. Boers. 2006. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis and Rheumatism 54(6): 1772–1777.PubMedCrossRef
21.
Shimizu, S., S. Shiozawa, K. Shiozawa, S. Imura, and T. Fujita. 1985. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis and Rheumatism 28(1): 25–31.PubMedCrossRef
22.
Bezerra, M.C., J.F. Carvalho, A.S. Prokopowitsch, and R.M. Pereira. 2005. RANK, RANKL and osteoprotegerin in arthritic bone loss. Brazilian Journal of Medicinal and Biological Research 38(2): 161–170.CrossRef
23.
Jilka, R.L., G. Hangoc, G. Girasole, G. Passeri, D.C. Williams, J.S. Abrams, B. Boyce, H. Broxmeyer, and S.C. Manolagas. 1992. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257(5066): 88–91.PubMedCrossRef
24.
Hembry, R.M., M.R. Bagga, J.J. Reynolds, and D.L. Hamblen. 1995. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Annals of the Rheumatic Diseases 54(1): 25–32.PubMedCrossRef
25.
Seeuws, S., P. Jacques, J. Van Praet, M. Drennan, J. Coudenys, T. Decruy, E. Deschepper, L. Lepescheux, P. Pujuguet, L. Oste, N. Vandeghinste, R. Brys, G. Verbruggen, and D. Elewaut. 2010. A multiparameter approach to monitor disease activity in collagen-induced arthritis. Arthritis Research & Therapy 12(4): R160. Epub 2010 Aug 23.CrossRef
26.
Kusano, K., C. Miyaura, M. Inada, T. Tamura, A. Ito, H. Nagese, K. Kamoi, and T. Suda. 1998. Regulation of matrix metalloproteinases (MMP-2-3-9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: Association of MMP induction with bone resorption. Endocrinology 139: 1338–1345.PubMedCrossRef
27.
Bingham, C.O. 2002. The pathogenesis of rheumatoid arthritis: Pivotal cytokines involved in bone degradation and inflammation. Journal of Rheumatology 65(Suppl): 3–9.PubMed
28.
Okada, Y., J.A. Lorenzo, A.M. Freeman, M. Tomita, S.G. Morham, L.G. Raisz, and C.C. Pilbeam. 2000. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. The Journal of Clinical Investigation 105(6): 823–832.PubMedCrossRef
29.
Liu, X.H., A. Kirschenbaum, S. Yao, and A.C. Levine. 2005. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology 146(4): 1991–1998.PubMedCrossRef
30.
Hikiji, H., T. Takato, T. Shimizu, and S. Ishii. 2008. The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease. Progress in Lipid Research 47(2): 107–126.PubMedCrossRef
31.
Keila, S., A. Kelner, and M. Weinreb. 2001. Systemic prostaglandin E2 increases cancellous bone formation and mass in aging rats and stimulates their bone marrow osteogenic capacity in vivo and in vitro. The Journal of Endocrinology 168(1): 131–139.PubMedCrossRef
32.
Gao, Q., P. Zhan, C.B. Alander, B.E. Kream, C. Hao, M.D. Breyer, C.C. Pilbeam, and L.G. Raisz. 2009. Effects of global or targeted deletion of the EP4 receptor on the response of osteoblasts to prostaglandin in vitro and on bone histomorphometry in aged mice. Bone 45(1): 98–103.PubMedCrossRef
33.
Kasukawa, Y., N. Miyakoshi, A.K. Srivastava, K. Nozaka, S. Maekawa, D.J. Baylink, S. Mohan, and E. Itoi. 2007. The selective cyclooxygenase-2 inhibitor celecoxib reduces bone resorption, but not bone formation, in ovariectomized mice in vivo. The Tohoku Journal of Experimental Medicine 211(3): 275–283.PubMedCrossRef
34.
Yoshida, K., H. Oida, T. Kobayashi, T. Maruyama, M. Tanaka, T. Katayama, K. Yamaguchi, E. Segi, T. Tsuboyama, M. Matsushita, K. Ito, Y. Ito, Y. Sugimoto, F. Ushikubi, S. Ohuchida, K. Kondo, T. Nakamura, and S. Narumiya. 2002. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proceeding of the National Academy of Sciences USA 99(7): 4580–4585.CrossRef
35.
Tsujisawa, T., H. Inoue, and T. Nishihara. 2005. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL. Journal of Bone and Mineral Research 20(1): 15–22.PubMedCrossRef
36.
Gallant, M.A., R. Samadfam, J.A. Hackett, J. Antoniou, J.L. Parent, and A.J. Brum-Fernandes. 2005. Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. Journal of Bone and Mineral Research 20(4): 672–681.PubMedCrossRef
37.
Durand, M., M.A. Gallant, and A.J. Brum-Fernandes. 2008. Prostaglandin D2 receptors control osteoclastogenesis and the activity of human osteoclasts. Journal of Bone and Mineral Research 23(7): 1097–1105.PubMedCrossRef
38.
Grundemar, L., and L. Ny. 1997. Pitfalls using metalloporphyrins in carbon monoxide research. Trends in Pharmacological Sciences 18(6): 193–195.PubMedCrossRef
39.
Kaizu, T., T. Tamaki, M. Tanaka, Y. Uchida, S. Tsuchihashi, A. Kawamura, and A. Kakita. 2003. Preconditioning with tin-protoporphyrin IX attenuates ischemia/reperfusion injury in the rat kidney. Kidney International 63(4): 1393–1403.PubMedCrossRef
Metadata
Title
Up-Regulation of the Inflammatory Response by Ovariectomy in Collagen-Induced Arthritis. Effects of Tin Protoporphyrin IX
Authors
Lidia Ibáñez
Maria José Alcaraz
Nuria Maicas
David Guede
José Ramón Caeiro
Marije I. Koenders
Wim B. van den Berg
Maria Luisa Ferrándiz
Publication date
01-12-2011
Publisher
Springer US
Published in
Inflammation / Issue 6/2011
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9266-4

Other articles of this Issue 6/2011

Inflammation 6/2011 Go to the issue

OriginalPaper

Effects of Caffeic Acid Phenethyl Ester (CAPE) on Hepatopulmonary Syndrome

OriginalPaper

Anti-inflammation Effects of Cordyceps sinensis Mycelium in Focal Cerebral Ischemic Injury Rats

OriginalPaper

Elevated Expression of Liver X Receptor Alpha (LXRα) in Myocardium of Streptozotocin-Induced Diabetic Rats

OriginalPaper

Study of Programmed Cell Death 1 (PDCD1) Gene Polymorphims in Iranian Patients with Ankylosing Spondylitis

OriginalPaper

Inflammation Alters Angiotensin Converting Enzymes (ACE and ACE-2) Balance in Rat Heart

OriginalPaper

Lipopolysaccharide-Mediated Induction of Calprotectin in the Submandibular and Parotid Glands of Mice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits